Vir Biotechnology (VIR) EBT (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of EBT data on file, last reported at -$125.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 3.78% year-over-year to -$125.5 million; the trailing twelve-month figure through Mar 2026 stood at -$442.3 million (up 23.61% YoY), and the FY2025 full-year result was -$437.8 million, up 16.31% from the prior year.
• EBT declined to -$125.5 million in Q1 2026, from -$43.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $921.9 million in Q1 2022 to a low of -$233.7 million in Q2 2022.
• A 5-year average of -$56.5 million and a median of -$125.5 million in 2026 frame the typical range for EBT.
• Peak annual rise in EBT reached 646.43% in 2022, while the deepest fall reached 477.79% in 2022.
• Tracing VIR's EBT over 5 years: stood at -$151.6 million in 2022, then gained by 20.36% to -$120.8 million in 2023, then advanced by 13.32% to -$104.7 million in 2024, then surged by 58.86% to -$43.1 million in 2025, then slumped by 191.51% to -$125.5 million in 2026.
• Business Quant data shows VIR's EBT at -$125.5 million in Q1 2026, -$43.1 million in Q4 2025, and -$163.0 million in Q3 2025.